Skip to content

Face Transplantation Clinical Trial

Protocol for Composite Facial Allograft Transplant

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01269164
Enrollment
3
Registered
2011-01-04
Start date
2010-07-31
Completion date
2020-11-30
Last updated
2023-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Facial Deformities

Keywords

Face Transplant, Facial Transplantation, Composite Facial Allograft Transplantation

Brief summary

The purpose of this study is to apply human facial allograft transplant to the subjects with severe facial deformities or disfigurements in order to provide adequate coverage, aesthetic appearance and functional outcome.

Detailed description

The human scalp and face define two important body units, both functionally and aesthetically. Traumatic deformities of the head and neck region resulting from burn injuries, gun shot wounds, or ablative tumor surgeries may involve the defect of the skin, subcutaneous tissue, muscle or the combination of all these elements. In most cases, the ideal reconstruction is very difficult to achieve. Sometimes, a major part of face along with the ear or the nose may be involved. The extensive scalp loss due to burn or avulsion injury is another deforming and psychologically debilitating condition presenting as a major reconstructive challenge. An ideal reconstructive procedure should replace the missing tissues and restore the motor and sensory function. Traditional reconstructive procedures of facial deformities involve skin grafting, local flap applications, tissue expansion, and prefabrication as well as free tissue transfers. The primary goal during facial reconstruction is restoration of the function and aesthetic appearance. To obtain satisfactory results, missing parts should be replaced only by tissues of the same color and texture. The purpose of this study is to apply human facial allograft transplant to the subjects with severe facial deformities or disfigurements in order to provide adequate coverage, aesthetic appearance and functional outcome.

Interventions

PROCEDURESurgical Procedure Composite Facial Transplant

Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation

Sponsors

United States Department of Defense
CollaboratorFED
The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Subject must be willing to sign the informed consent and agree to all follow up procedures, including the realistic understanding of the impact of face allotransplantation on their lifestyle * Subjects will be evaluated by plastic surgeon to assess indications for facial allotransplantations based on severity and complexity of facial deformity * Subjects ages 18-60. * Subject must be willing to undergo a psychiatric and social services pre-transplantation evaluation * Subject must be willing to undergo major face surgery * Subject must be a candidate for general anesthesia * Subjects must be willing to comply with post transplant physical therapy. * Subject must be willing and able to receive potent drugs to induce and maintain immunosuppression and follow the infection prophylaxis protocol * Subject must be willing to receive standard vaccinations such as influenza, pneumococcus, and hepatitis B. * Subjects must be free of malignant tumors for 5 or more years with the exception of certain skin cancer.

Exclusion criteria

* Subject that shows history of persistent non-compliance * Findings of the psychiatric evaluation that may indicate non-compliance or mental instability * Presence of an active infection including Human Immunodeficiency Virus, mycobacteria, hepatitis B, and hepatitis C * Presence of an occult infection for example, dental abscess, UTI, tuberculosis, or history of systemic/occult infection within 3 months of surgery * Any current Chemical Dependency including alcohol * Subjects at high risk for the recurrence of malignancy with the exception of certain skin cancers * Any diagnosis that the qualifying plastic surgeon feels would put the subject at high risk for the surgical procedure of face transplantation * Subjects who do not have adequate donor site tissue available for coverage in the event of face transplant failure

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the success of the face transplantPatients will be carefully screened and monitored post-operatively for signs of rejection or flap failure for 5 years.Demonstrate stable engraftment and restoration of facial skin/bone coverage and sensory-motor function in recipients of composite tissue allografts of vascularized skin, bone, and soft tissue augments(nose, ear, lips, eyelids, etc)under standard immunopression protocol.

Secondary

MeasureTime frameDescription
Evaluate tolerogenic properties of the immunosuppression protocolPatients will be carefully screened and monitored post-operatively for signs of rejection or flap failure for 5 years.Characterize tolerogenic properties of our immunosuppression protocol, by monitoring of donor specific chimerism and presence of T regulatory cells in the face allograft transplant recipients.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026